Jolkinolide B Inhibits the Progression of Hepatocellular Carcinoma by Regulating Musashi-2 Protein

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Apr 17

PMID 38630658

Authors

Tianchun Wu

Han Yang

Jinjin Li

Hongbo Fang

Xiaoyi Shi

Jie Li

Liushun Feng

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths. However, the HCC treatment is still challenging. Herein, we aimed to reveal the anti-tumor effect of Jolkinolide B in HCC cell lines Huh-7 and SK-Hep-1. The results showed that Jolkinolide B inhibited the migration, invasion, and epithelial-to-mesenchymal transition(EMT) of HCC cells. In addition, Jolkinolide B induced HCC cell apoptosis by upregulating Bax and downregulating BCL-2 expressions. Furthermore, we demonstrated that Jolkinolide B inactivated the β-catenin signaling and reduced Musashi-2 expression. Finally, we revealed that Musashi-2 overexpression reversed the Jolkinolide B-induced anti-HCC effect. Overall, we proved that Jolkinolide B is a potential candidate for treating HCC.

References

Pinter M, Jain R, Duda D . The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2020; 7(1):113-123. PMC: 8265820. DOI: 10.1001/jamaoncol.2020.3381. View

Novoa Diaz M, Martin M, Gentili C . Tumor microenvironment involvement in colorectal cancer progression Wnt/β-catenin pathway: Providing understanding of the complex mechanisms of chemoresistance. World J Gastroenterol. 2022; 28(26):3027-3046. PMC: 9331520. DOI: 10.3748/wjg.v28.i26.3027. View

Aghdaei H, Kadijani A, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H . An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J. 2018; 6(7):1074-1081. PMC: 6137581. DOI: 10.1177/2050640618774637. View

Liu Y, Fan Y, Wang X, Huang Z, Shi K, Zhou B . Musashi-2 is a prognostic marker for the survival of patients with cervical cancer. Oncol Lett. 2018; 15(4):5425-5432. PMC: 5844186. DOI: 10.3892/ol.2018.8077. View

Wang Y, Shen S, Liu L, Zhang X, Liu D, Liu N . Jolkinolide B inhibits proliferation or migration and promotes apoptosis of MCF-7 or BT-474 breast cancer cells by downregulating the PI3K-Akt pathway. J Ethnopharmacol. 2021; 282:114581. DOI: 10.1016/j.jep.2021.114581. View

Ren J, Yang Y, Peng T, Xu D . Predictive value of β-catenin in bladder cancer: a systematic review and meta-analysis. Biosci Rep. 2020; 40(9). PMC: 7475297. DOI: 10.1042/BSR20202127. View

Chen F, Dai L, An J, Zeng N, Chen L, Shen Y . Diagnostic accuracy of E-cadherin for malignanteffusions: a systematic review and meta-analysis. Postgrad Med J. 2019; 96(1139):530-536. DOI: 10.1136/postgradmedj-2019-137025. View

Good P, Yoda A, Sakakibara S, Yamamoto A, Imai T, Sawa H . The human Musashi homolog 1 (MSI1) gene encoding the homologue of Musashi/Nrp-1, a neural RNA-binding protein putatively expressed in CNS stem cells and neural progenitor cells. Genomics. 1998; 52(3):382-4. DOI: 10.1006/geno.1998.5456. View

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

10.

Matly A, Quinn J, McMillan D, Park J, Edwards J . The relationship between β-catenin and patient survival in colorectal cancer systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021; 163:103337. DOI: 10.1016/j.critrevonc.2021.103337. View

11.

Liu L, Shi R, Chen Z . Paeonol exerts anti‑tumor activity against colorectal cancer cells by inducing G0/G1 phase arrest and cell apoptosis via inhibiting the Wnt/β‑catenin signaling pathway. Int J Mol Med. 2020; 46(2):675-684. PMC: 7307818. DOI: 10.3892/ijmm.2020.4629. View

12.

Yang Z, Li J, Shi Y, Li L, Guo X . Increased musashi 2 expression indicates a poor prognosis and promotes malignant phenotypes in gastric cancer. Oncol Lett. 2019; 17(3):2599-2606. PMC: 6365935. DOI: 10.3892/ol.2019.9889. View

13.

Tan D, Ng C, Lin S, Pan X, Tay P, Lim W . Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022; 23(4):521-530. PMC: 9718369. DOI: 10.1016/S1470-2045(22)00078-X. View

14.

Zhang H, Qian J, Jin M, Fan L, Fan S, Pan H . Jolkinolide B induces cell cycle arrest and apoptosis in MKN45 gastric cancer cells and inhibits xenograft tumor growth in vivo. Biosci Rep. 2022; 42(6). PMC: 9245080. DOI: 10.1042/BSR20220341. View

15.

Kaszak I, Witkowska-Pilaszewicz O, Niewiadomska Z, Dworecka-Kaszak B, Toka F, Jurka P . Role of Cadherins in Cancer-A Review. Int J Mol Sci. 2020; 21(20). PMC: 7589192. DOI: 10.3390/ijms21207624. View

16.

Yang C, Zhang W, Wang L, Kazobinka G, Han X, Li B . Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway. Lab Invest. 2016; 96(9):950-8. DOI: 10.1038/labinvest.2016.71. View

17.

Kharas M, Lengner C, Al-Shahrour F, Bullinger L, Ball B, Zaidi S . Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010; 16(8):903-8. PMC: 3090658. DOI: 10.1038/nm.2187. View

18.

Wang M, Qin S, Zhang S, Li G, Yu Z, Wang K . Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/β-catenin pathway. Am J Cancer Res. 2015; 5(3):1089-100. PMC: 4449437. View

19.

Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15(3):178-96. PMC: 4240281. DOI: 10.1038/nrm3758. View

20.

Zhou T, Zhang A, Kuang G, Gong X, Jiang R, Lin D . Baicalin inhibits the metastasis of highly aggressive breast cancer cells by reversing epithelial-to-mesenchymal transition by targeting β-catenin signaling. Oncol Rep. 2017; 38(6):3599-3607. DOI: 10.3892/or.2017.6011. View